Nxera Pharma Co., Ltd. (FRA:JSS)
Germany · Delayed Price · Currency is EUR 4.780
+0.280 (6.22%)
At close: Nov 28, 2025
Nxera Pharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 28,700 | 28,835 | 12,766 | 15,569 | 17,712 | 8,842 | Upgrade | |
Revenue Growth (YoY) | -1.96% | 125.87% | -18.00% | -12.10% | 100.32% | -9.09% | Upgrade |
Cost of Revenue | 8,273 | 7,616 | 3,102 | 926 | 933 | 761 | Upgrade |
Gross Profit | 20,427 | 21,219 | 9,664 | 14,643 | 16,779 | 8,081 | Upgrade |
Selling, General & Admin | 15,708 | 12,924 | 8,167 | 3,535 | 3,138 | 2,525 | Upgrade |
Research & Development | 14,499 | 11,816 | 10,075 | 7,454 | 5,931 | 3,793 | Upgrade |
Other Operating Expenses | -1,296 | 12 | 23 | - | -2 | -1 | Upgrade |
Operating Expenses | 28,911 | 27,843 | 20,063 | 11,831 | 9,869 | 7,227 | Upgrade |
Operating Income | -8,484 | -6,624 | -10,399 | 2,812 | 6,910 | 854 | Upgrade |
Interest Expense | -1,915 | -769 | -787 | -673 | -518 | -207 | Upgrade |
Interest & Investment Income | 1,192 | 1,478 | 1,225 | 236 | 4 | 35 | Upgrade |
Earnings From Equity Investments | - | - | - | -429 | 50 | -356 | Upgrade |
Currency Exchange Gain (Loss) | - | 27 | -329 | 313 | 22 | -217 | Upgrade |
Other Non Operating Income (Expenses) | - | 1,288 | -282 | 696 | -3,105 | 1,402 | Upgrade |
EBT Excluding Unusual Items | -9,207 | -4,600 | -10,572 | 2,955 | 3,363 | 1,511 | Upgrade |
Gain (Loss) on Sale of Investments | - | 1 | -46 | -1,877 | 208 | -18 | Upgrade |
Gain (Loss) on Sale of Assets | - | -63 | -62 | - | - | - | Upgrade |
Asset Writedown | - | - | - | - | -3,138 | 129 | Upgrade |
Pretax Income | -9,207 | -4,662 | -10,680 | 1,078 | 433 | 1,622 | Upgrade |
Income Tax Expense | -3,063 | 176 | -3,487 | 696 | -584 | 143 | Upgrade |
Earnings From Continuing Operations | -6,144 | -4,838 | -7,193 | 382 | 1,017 | 1,479 | Upgrade |
Net Income | -6,144 | -4,838 | -7,193 | 382 | 1,017 | 1,479 | Upgrade |
Net Income to Common | -6,144 | -4,838 | -7,193 | 382 | 1,017 | 1,479 | Upgrade |
Net Income Growth | - | - | - | -62.44% | -31.24% | 3.28% | Upgrade |
Shares Outstanding (Basic) | 90 | 90 | 83 | 82 | 81 | 79 | Upgrade |
Shares Outstanding (Diluted) | 90 | 90 | 83 | 83 | 82 | 79 | Upgrade |
Shares Change (YoY) | 2.21% | 8.74% | -0.09% | 0.71% | 3.16% | 2.60% | Upgrade |
EPS (Basic) | -68.17 | -53.92 | -87.17 | 4.67 | 12.53 | 18.78 | Upgrade |
EPS (Diluted) | -68.17 | -53.92 | -87.18 | 4.63 | 12.40 | 18.59 | Upgrade |
EPS Growth | - | - | - | -62.66% | -33.30% | 0.49% | Upgrade |
Free Cash Flow | -13,967 | -8,244 | -6,077 | 9,675 | 6,902 | 4,580 | Upgrade |
Free Cash Flow Per Share | -154.97 | -91.87 | -73.65 | 117.14 | 84.17 | 57.62 | Upgrade |
Gross Margin | 71.17% | 73.59% | 75.70% | 94.05% | 94.73% | 91.39% | Upgrade |
Operating Margin | -29.56% | -22.97% | -81.46% | 18.06% | 39.01% | 9.66% | Upgrade |
Profit Margin | -21.41% | -16.78% | -56.34% | 2.45% | 5.74% | 16.73% | Upgrade |
Free Cash Flow Margin | -48.67% | -28.59% | -47.60% | 62.14% | 38.97% | 51.80% | Upgrade |
EBITDA | -4,198 | -2,640 | -7,921 | 4,157 | 8,188 | 2,204 | Upgrade |
EBITDA Margin | -14.63% | -9.16% | -62.05% | 26.70% | 46.23% | 24.93% | Upgrade |
D&A For EBITDA | 4,286 | 3,984 | 2,478 | 1,345 | 1,278 | 1,350 | Upgrade |
EBIT | -8,484 | -6,624 | -10,399 | 2,812 | 6,910 | 854 | Upgrade |
EBIT Margin | -29.56% | -22.97% | -81.46% | 18.06% | 39.01% | 9.66% | Upgrade |
Effective Tax Rate | - | - | - | 64.56% | - | 8.82% | Upgrade |
Advertising Expenses | - | 2,238 | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.